the DBL report

Issue #126, May 2022

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on March 15, 2022. The Committee reviewed Manufacturer submissions for fifteen (15) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of two (2) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, twenty-five (25) Drug Products underwent Expedited Review for listing on the *ADBL* effective May 1, 2022.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.php

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* effective April 1, 2022:

- **ENTUZITY* 500 unit/mL injection kwikpen** (insulin human biosynthetic (regular)) (LIL) via Special Authorization (SA)
- **OFEV* 100 mg & 150 mg capsules** (nintedanib esilate) (BOE) via SA for the indication of Chronic Fibrosing Interstitial Lung Disease with a Progressive Phenotype

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* effective May 1, 2022:

- **KESIMPTA* 20 mg/0.4 mL prefilled pen** (ofatumumab) (NOV) via SA
- **MAR-TRIENTINE* 250 mg capsule** (trientine hydrochloride) (MAR) via SA

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.php.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (05/2022)

Highlights of Diabetes Supplies Added

The following brand of blood glucose test strips was added to the *ADBL* via Restricted Benefit effective May 1, 2022:

- **TYKESS* blood glucose test strips** (TTC)

Highlights of Drug Products Added

The following Drug Product was reviewed by the Expert Committee and added to the *ADBL* effective May 1, 2022:

- **SANDOZ DIMETHYL FUMARATE* 240 mg delayed-release capsule** (dimethyl fumarate) (SDZ) via SA

Highlights of Biosimilar Drug Products Added

The following Biosimilar Drug Products were added to the *ADBL* effective May 1, 2022:

- **ABRILADA* 40 mg/0.8 mL injection pen & syringe** (adalimumab) (PFI) via SA for the indications of Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Crohn's Disease (CD), Plaque Psoriasis (PsO), Psoriatic Arthritis (PsA), Polyarticular Juvenile Idiopathic Arthritis (pJIA), Rheumatoid Arthritis (RA) and Ulcerative Colitis (UC)

Highlights of Changes to Currently Listed Products

The Restricted Benefit criteria for coverage for the following Devices have been revised effective April 1, 2022:

- **DEXCOM G6* SENSOR & DEXCOM G6* TRANSMITTER** for continuous glucose monitoring (COM)
- **GUARDIAN LINK* TRANSMITTER (670G & 770G PUMPS), GUARDIAN* SENSOR & GUARDIAN CONNECT* TRANSMITTER** for continuous glucose monitoring (MET)

The Special Authorization administrative preamble has been removed for the following Drug Products, effective May 1, 2022:

- **AMGEVITA* 40 mg/0.8 mL injection syringe & autoinjector pen** (adalimumab) (AMG) via SA for the indications of AS, HS, CD, PsO, PsA, pJIA, RA & UC
- **AMGEVITA* 20 mg/0.4 mL prefilled syringe** (adalimumab) (AMG) via SA for the indication of pJIA
- **HADLIMA* 40 mg/0.8 mL autoinjector & injection syringe** (adalimumab) (SSB) via SA for the indications of AS, HS, CD, PsO, PsA, pJIA, RA & UC
- **HULIO* 40 mg/0.8 mL injection pen & syringe** (adalimumab) (BGP) via SA for the indications of AS, HS, CD, PsO, PsA, pJIA, RA & UC
- **HYRIMOZ* 40 mg/0.8 mL injection pen & syringe** (adalimumab) (SDZ) via SA for the indications of AS, HS, CD, PsO, PsA, pJIA, RA & UC
- **HYRIMOZ* 20 mg/0.4 mL injection syringe** (adalimumab) (SDZ) via SA for the indication of pJIA
- **IDACIO* 40 mg/0.8 mL injection pen & syringe** (adalimumab) (FKC) via SA for the indications of AS, HS, CD, PsO, PsA, pJIA, RA & UC

Delisted Products

The following Drug Products were delisted from the *ADBL* effective April 1, 2022 due to the Alberta Biosimilar Initiative:

- **NOVORAPID 100 unit/mL injection vial and cartridge & NOVORAPID FLEXTOUCH 100 unit/mL injection pen** (insulin aspart) (NNA)

The following Drug Products were delisted from the *ADBL* effective May 1, 2022 due to the Alberta Biosimilar Initiative:

- **HUMIRA 20 mg/0.2 mL & 40 mg/0.8 mL injection syringes** (adalimumab) (ABV)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*
ABC 81171 (05/2022)